Abstract:OBJECTIVE:To investigate the effect of metformin on the proliferation and cell apoptosis of oral squamous cell carcinoma (OSCC) (HSC-3, HSC-4) in vitro and in vivo.METHODS:HSC-3, HSC-4 cells were treated with metformin at different concentration (2-50 mmol/L) for 24, 48 or 72 hours. In vitro cell proliferation ability was determined by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and colony formation assay. Cell cycle progression was assessed by flow cytometry. Cell apoptosis was tested by both TdT-mediated dUTP nick-end labeling (TUNEL) assay and flow cytometry. The activation of related cell markers was examined by immunohistochemistry. Xenograft mouse model was used to demonstrate the in vivo anti-tumor effect of metformin. A total of 30 BALB/c mice were randomly divided into control groups (water + phosphate buffer saline, PBS) and treatment groups (pre-oral, oral or intraperitoneal injection). Each group had 6 mice. The tumor size was measured once every three days until endpoint (35 days). After sacrificing the mice, tumor tissue was removed, sectioning and then analyzed by TUNEL or immunohistochemistry (IHC) assays.RESULTS:Metformin inhibited proliferation and colony formation of HSC-3, HSC-4 in a time- and dose-dependent manner. The cell proliferation was significantly reduced when treated with 5, 10, 20 and 40 mmol/L metformin for 48 and 72 hours (P < 0.05).The colony formation of OSCC cells treated with metformin for 72 hours in vitro had the same result. Treated with 2, 20 and 50 mmol/L metformin for 24 hours increased the ratio of G0/G1 1.2-1.8 fold compared with the control group on HSC-4 cell. The percentage of apoptosis cell rose from 10% (control) to around 30% (treatment) in vitro. Metformin also decreased the size of xenografts by 82.5% (pre-oral), 63.9% (oral), and 62.8% (oral or intraperitoneal injection). The percentage of apoptosis cell rose from lower than 10% (control) to 70% (pre-oral), 50% (oral), and 25% (oral or intraperitoneal injection). The percentage of PCNA positive cell was lower than 60% (control group was normalized to 100%).CONCLUSIONS:Metformin could inhibit the growth of OSCC cell line (HSC-3, HSC-4) by reducing cell proliferation and increasing cell apoptosis in vitro and in vivo. Therefore metformin could be a potential new treatment candidate for human OSCC.

Metformin Induces Cytotoxicity in Oral Squamous Cell Carcinoma Cells by Targeting CCN1/Akt-Axis

Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition

In Vitro and in Vivo Anti-Tumor Effect of Metformin As a Novel Therapeutic Agent in Human Oral Squamous Cell Carcinoma.

Inhibition of Autophagy Promotes the Anti-Tumor Effect of Metformin in Oral Squamous Cell Carcinoma

[The Inhibitory Effect of Metformin on Oral Squamous Cell Carcinoma].

Fibroblasts Rescue Oral Squamous Cancer Cell from Metformin-Induced Apoptosis Via Alleviating Metabolic Disbalance and Inhibiting AMPK Pathway

Transcriptional and H3K27ac related genome profiles in oral squamous cell carcinoma cells treated with metformin

Metformin Inhibited Esophageal Squamous Cell Carcinoma Proliferation in Vitro and in Vivo and Enhanced the Anti-Cancer Effect of Cisplatin

Metformin and 4SC-202 synergistically promote intrinsic cell apoptosis by accelerating ΔNp63 ubiquitination and degradation in oral squamous cell carcinoma.

Role of C-Met in the Progression of Human Oral Squamous Cell Carcinoma and Its Potential As a Therapeutic Target.

Metformin Sensitizes the Response of Oral Squamous Cell Carcinoma to Cisplatin Treatment Through Inhibition of NF-κB/HIF-1α Signal Axis

Reduction Behavior Induced by HL010183, a Metformin Derivative Against the Growth of Cutaneous Squamous Cell Carcinoma.

Metformin Inhibits Mtor and C-Myc by Decreasing YAP Protein Expression in OSCC Cells

Integrin Β1-Mediated Cell–Cell Adhesion Augments Metformin-Induced Anoikis

Metformin overcomes chemoresistance by regulating stemness via KLF4 in oral squamous cell carcinoma

Metformin Promotes AMP-activated Protein Kinase-independent Suppression of ΔNp63α Protein Expression and Inhibits Cancer Cell Viability

Abstract 2856: Inhibition of Glycolysis Sensitizes Cancer Cells to Metformin-Induced Anoikis

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis

Metformin Inhibits the Development of Hypopharyngeal Squamous Cell Carcinoma Through Circ_0003214-Mediated MiR-489-3p-ADAM10 Pathway

Metformin Inhibits Cell Growth by Upregulating Microrna-26A in Renal Cancer Cells.